Science & technology

R&D pipeline

Taking life-changing innovations all the way

At Novo Nordisk, our R&D pipeline reflects our long-standing commitment to driving change to defeat diabetes and other serious chronic conditions.

Our scientists are currently working on novel and innovative treatments to address the unmet needs of people living with diabetes, obesity, haemophilia, growth disorders and non-alcoholic steatohepatitis (NASH).


Browse our entire R&D pipeline by study phase, or select a specific therapy areas. Click on a candidate to access up-to-date trial information.

Choose therapy area

Choose phase

Phase 1

Type 1 and 2 diabetes. Phase 1.

FSI965 is a next-generation basal insulin.

Obesity. Phase 1.

PYY 1875 is an appetite regulating hormone and is tested alone and in combination with semaglutide.

Obesity. Phase 1.

Combination of amylin (AM833) and semaglutide.

Obesity. Phase 1.

Human GDF15, is a stress-induced cytokine with multiple effects, one being appetite regulation leading to weight loss.

Haemophilia A. Phase 1.

Mim8 is a next-generation factor VIII mimetic bi-specific antibody for subcutaneous prophylaxis treatment of haemophilia A regardless of inhibitor status.

Type 2 diabetes. Phase 1.

The once-weekly combination of once-weekly insulin LAI287 and once-weekly injectable GLP-1 semaglutide.

Sickle cell disease. Phase 1.

EPI01 is an oral combination product for treatment of sickle cell disease.

Insulin 147 & PCSK9i. Phase 1

Insulin 147 is a long-acting insulin analogue coupled via a linker to a proprietary PCSK9 inhibitory peptide for once-daily subcutaneous administration to people with diabetes in need of basal insulin and LDL cholesterol lowering

OW Sema + GIP

The trial is testing the fixed ratio combination formulation of semaglutide and a once-weekly human GIP analogue

Cardiovascular disease. Phase 1.

Subcutaneous version of PCSK9i intended to treat people with hypercholesterolaemia.

Phase 2

Type 1 and 2 diabetes. Phase 2.

A long-acting basal insulin analogue intended for once weekly dosing.

Type 1 diabetes. Phase 2.

A beta-cell preservation treatment intended for people newly diagnosed with type 1 diabetes.

Obesity. Phase 2.

A long-acting amylin analogue intended as treatment for obesity.

Macrilen. Phase 2

Trial to investigate Macrilen as a diagnosis tool for growth hormone deficiency 

NASH. Phase 2.

A long-acting GLP-1 analogue intended as once-daily treatment for non-alcoholic fatty liver disease (NASH).

Phase 3

Obesity. Phase 3.

A long-acting GLP-1 analogue intended as a once-weekly treatment for obesity.

Haemophilia A and B. Phase 3.

A monoclonal antibody against Tissue Factor Pathway Inhibitor (TFPI) intended for bleeding prevention after subcutaneous administration.

Growth disorder. Phase 3.

A long-acting human growth hormone intended to offer once-weekly injections.


Somapacitan – QW AGHD

Somapacitan once-weekly growth hormone is filled for the Adult Growth Hormone deficiency indication

Explore more

Obesity R&D at Novo Nordisk A/S, Måløv, Denmark, 2015

The technology behind tablets

What if medicines injected by millions could be delivered in tablets? Our research and development team is working on an answer.

NNPC2J0046 CPiH Innovation concept Photoshoot-OOP only;Novo Nordisk; New product Commercialization (NPC);Patrick Bosak; Oct 3-9; scientists/employees in their lab in Copenhagen Malov and Soeborg; equipment; b-roll video, video interview; portraits on white

Finding the right target

Discovering better treatments takes research technologies that help unravel the biological complexity behind chronic diseases.

We don't wait, we drive change

We don't wait, we drive change

Do you feel at home in a lab? See the current opportunities in our global research and development team.